Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection - PubMed (original) (raw)
Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection
Paul J Maglione et al. J Immunol. 2008.
Abstract
The critical role of cellular immunity during tuberculosis (TB) has been extensively studied, but the impact of Abs upon this infection remains poorly defined. Previously, we demonstrated that B cells are required for optimal protection in Mycobacterium tuberculosis-infected mice. FcgammaR modulate immunity by engaging Igs produced by B cells. We report that C57BL/6 mice deficient in inhibitory FcgammaRIIB (RIIB-/-) manifested enhanced mycobacterial containment and diminished immunopathology compared with wild-type controls. These findings corresponded with enhanced pulmonary Th1 responses, evidenced by increased IFN-gamma-producing CD4+ T cells, and elevated expression of MHC class II and costimulatory molecules B7-1 and B7-2 in the lungs. Upon M. tuberculosis infection and immune complex engagement, RIIB-/- macrophages produced more of the p40 component of the Th1-promoting cytokine IL-12. These data strongly suggest that FcgammaRIIB engagement can dampen the TB Th1 response by attenuating IL-12p40 production or activation of APCs. Conversely, C57BL/6 mice lacking the gamma-chain shared by activating FcgammaR had enhanced susceptibility and exacerbated immunopathology upon M. tuberculosis challenge, associated with increased production of the immunosuppressive cytokine IL-10. Thus, engagement of distinct FcgammaR can divergently affect cytokine production and susceptibility during M. tuberculosis infection.
Similar articles
- Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis.
Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, Flynn JL. Caruso AM, et al. J Immunol. 1999 May 1;162(9):5407-16. J Immunol. 1999. PMID: 10228018 - Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL-12p40.
Kinjo Y, Kawakami K, Uezu K, Yara S, Miyagi K, Koguchi Y, Hoshino T, Okamoto M, Kawase Y, Yokota K, Yoshino K, Takeda K, Akira S, Saito A. Kinjo Y, et al. J Immunol. 2002 Jul 1;169(1):323-9. doi: 10.4049/jimmunol.169.1.323. J Immunol. 2002. PMID: 12077261 - Mice deficient in LRG-47 display increased susceptibility to mycobacterial infection associated with the induction of lymphopenia.
Feng CG, Collazo-Custodio CM, Eckhaus M, Hieny S, Belkaid Y, Elkins K, Jankovic D, Taylor GA, Sher A. Feng CG, et al. J Immunol. 2004 Jan 15;172(2):1163-8. doi: 10.4049/jimmunol.172.2.1163. J Immunol. 2004. PMID: 14707092 - T cells and adaptive immunity to Mycobacterium tuberculosis in humans.
Jasenosky LD, Scriba TJ, Hanekom WA, Goldfeld AE. Jasenosky LD, et al. Immunol Rev. 2015 Mar;264(1):74-87. doi: 10.1111/imr.12274. Immunol Rev. 2015. PMID: 25703553 Review. - [Novel vaccines against M. tuberculosis].
Okada M. Okada M. Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
Cited by
- Fc-engineered antibodies promote neutrophil-dependent control of Mycobacterium tuberculosis.
Irvine EB, Nikolov A, Khan MZ, Peters JM, Lu R, Sixsmith J, Wallace A, van Woudenbergh E, Shin S, Karpinski W, Hsiao JC, Casadevall A, Bryson BD, Cavacini L, Grace PS, Alter G, Fortune SM. Irvine EB, et al. Nat Microbiol. 2024 Sep;9(9):2369-2382. doi: 10.1038/s41564-024-01777-9. Epub 2024 Aug 22. Nat Microbiol. 2024. PMID: 39174703 Free PMC article. - From pathogenesis to antigens: the key to shaping the future of TB vaccines.
Yang H, Lei X, Chai S, Su G, Du L. Yang H, et al. Front Immunol. 2024 Jul 23;15:1440935. doi: 10.3389/fimmu.2024.1440935. eCollection 2024. Front Immunol. 2024. PMID: 39108269 Free PMC article. Review. - The multivalency game ruling the biology of immunity.
Aiassa LV, Battaglia G, Rizzello L. Aiassa LV, et al. Biophys Rev (Melville). 2023 Dec 29;4(4):041306. doi: 10.1063/5.0166165. eCollection 2023 Dec. Biophys Rev (Melville). 2023. PMID: 38505426 Free PMC article. Review. - Vaccine development against tuberculosis before and after Covid-19.
Kaufmann SHE. Kaufmann SHE. Front Immunol. 2023 Nov 15;14:1273938. doi: 10.3389/fimmu.2023.1273938. eCollection 2023. Front Immunol. 2023. PMID: 38035095 Free PMC article. Review. - Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan.
Liu Y, Chen T, Zhu Y, Furey A, Lowary TL, Chan J, Bournazos S, Ravetch JV, Achkar JM. Liu Y, et al. JCI Insight. 2023 Oct 23;8(20):e167960. doi: 10.1172/jci.insight.167960. JCI Insight. 2023. PMID: 37733444 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- P01 AI063537/AI/NIAID NIH HHS/United States
- P30 AI051519/AI/NIAID NIH HHS/United States
- R01 AI03377414/AI/NIAID NIH HHS/United States
- R01 AI50732/AI/NIAID NIH HHS/United States
- R01 HL071241/HL/NHLBI NIH HHS/United States
- T32 AI007506/AI/NIAID NIH HHS/United States
- U54 AI05715805/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous